Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction

被引：13

作者：

Bedrouni, Wassim ^{[1
]}

Sharma, Abhinav ^{[2
]}

Pitt, Bertram ^{[3
]}

Lam, Carolyn S. P. ^{[4
,5
]}

Ni, Jiayi ^{[2
]}

Ferreira, Joao Pedro ^{[6
,7
,8
]}

McMurray, John ^{[9
]}

Giannetti, Nadia ^{[6
,7
]}

Girerd, Nicolas ^{[2
]}

Rossignol, Patrick ^{[6
,7
]}

Solomon, Scott D. ^{[10
]}

Claggett, Brian ^{[10
]}

Pocock, Stuart ^{[11
]}

Huynh, Thao ^{[2
]}

Zannad, Faiez ^{[6
,7
]}

机构：

[1] McGill Univ, Hlth Ctr, Dept Med, Montreal, PQ, Canada

[2] McGill Univ, Hlth Ctr, Div Cardiol, Montreal, PQ, Canada

[3] Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI USA

[4] Natl Heart Ctr Singapore, Dept Cardiol, Singapore, Singapore

[5] Duke Natl Univ Singapore, Singapore, Singapore

[6] Univ Lorraine, Invest Clin Plurithemat 1433, Nancy, France

[7] Univ Lorraine, Inserm U1116, CHRU Nancy, FCRIN INI CRCT Cardiovasc & Renal Clin Trialists, Nancy, France

[8] Univ Porto, Fac Med, Dept Surg & Physiol, Cardiovasc Res & Dev Ctr, Porto, Portugal

[9] Univ Glasgow, BHF Cardiovasc Res Ctr, Glasgow, Scotland

[10] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA

[11] London Sch Hyg & Trop Med, Dept Med Stat, London, England

来源：

CIRCULATION-HEART FAILURE | 2022年 / 15卷 / 10期

关键词：

eplerenone; morbidity; myocardial infarction; prognosis; spironolactone; SPIRONOLACTONE; DYSFUNCTION; EPLERENONE; MORTALITY;

D O I：

10.1161/CIRCHEARTFAILURE.121.009295

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 5 条

[1] Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
Pitt, B
Remme, W
Zannad, F
Neaton, J
Martinez, F
Roniker, B
Bittman, R
Hurley, S
Kleiman, J
Gatlin, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) : 1309 - 1321
[2] Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure
Pitt, B
White, H
Nicolau, J
Martinez, F
Gheorghiade, M
Aschermann, M
van Veldhuisen, DJ
Zannad, F
Krum, H
Mukherjee, R
Vincent, J
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (03) : 425 - 431
[3] The effect of spironolactone on morbidity and mortality in patients with severe heart failure
Pitt, B
Zannad, F
Remme, WJ
Cody, R
Castaigne, A
Perez, A
Palensky, J
Wittes, J
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) : 709 - 717
[4] Spironolactone for Heart Failure with Preserved Ejection Fraction
Pitt, Bertram
Pfeffer, Marc A.
Assmann, Susan F.
Boineau, Robin
Anand, Inder S.
Claggett, Brian
Clausell, Nadine
Desai, Akshay S.
Diaz, Rafael
Fleg, Jerome L.
Gordeev, Ivan
Harty, Brian
Heitner, John F.
Kenwood, Christopher T.
Lewis, Eldrin F.
O'Meara, Eileen
Probstfield, Jeffrey L.
Shaburishvili, Tamaz
Shah, Sanjiv J.
Solomon, Scott D.
Sweitzer, Nancy K.
Yang, Song
McKinlay, Sonja M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (15) : 1383 - 1392
[5] Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Zannad, Faiez
McMurray, John J. V.
Krum, Henry
van Veldhuisen, Dirk J.
Swedberg, Karl
Shi, Harry
Vincent, John
Pocock, Stuart J.
Pitt, Bertram
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (01) : 11 - 21

← 1 →